AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Sponsor: Allist Pharmaceuticals, Inc.
Terminated
Indications have been approved for marketing
Other terminated trials from Allist Pharmaceuticals, Inc.
More terminations from Allist Pharmaceuticals, Inc.
Other Advanced NSCLC trials with similar outcome
This NA trial investigates Advanced NSCLC and is currently terminated or withdrawn. Allist Pharmaceuticals, Inc. leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
May 2025 — Present [monthly]
Terminated NA
Status: Unknown → Terminated
-
Sep 2024 — May 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting NA
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Not Yet Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2019 [monthly]
Not Yet Recruiting NA
-
May 2017 — Jun 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allist Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .